Arshiya Shamim

Dr. Arshiya Shamim

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2024 in Efood
Verified
Journal Article
Open access
SASana Ahmad
Sana Ahmad
FAFarogh Ahsan
Farogh Ahsan
JAJaved Akhtar Ansari
Javed Akhtar Ansari
TMTarique Mahmood
Tarique Mahmood
ASArshiya Shamim
Arshiya Shamim
MKMithilesh Kesari
Mithilesh Kesari
A natural product is a compound or substance originating from a living organism and found in nature. Daidzein belongs to the class of bioflavonoids, which are plant‐derived compounds with various biological activities. Predominantly exists in soybeans and several legumes in either glycoside or aglycone forms. Its primary chemical constituents include metabolites like equol and trihydroxy isoflavone, generated through the influence of intestinal bacteria. Daidzein has exhibited pharmacological impacts on different ailments, including cardiovascular disease, cancer, diabetes, skin disorders, osteoporosis, and neurodegenerative disorders. Daidzein's mechanisms of action involve interactions with estrogen receptors, as well as its antioxidant and anti‐inflammatory properties, along with its ability to regulate apoptosis and the cell cycle. In efforts to enhance its solubility, stability, bioavailability, and targeting, daidzein has been innovatively formulated into novel dosage forms, including nanoparticles, liposomes, microemulsions, and nanosuspensions. As a promising nutraceutical, daidzein presents multiple health benefits and holds potential for various clinical applications. Additional investigation is required to comprehend the molecular mechanisms of this phenomenon and assess its safety. The purpose of this review is to provide a short description of the therapeutic properties, chemical composition, traditional use, toxicology profile, new insights on the dosage form, and future prospects of daidzein.

5 March 2020 in Journal of Basic and Clinical Physiology and Pharmacology
Verified
Journal Article
Closed access
PDF file
FAFarogh Ahsan
Farogh Ahsan
TMTarique Mahmood
Tarique Mahmood
MSMohammed Haris Siddiqui
Mohammed Haris Siddiqui
SUShazia Usmani
Shazia Usmani
PBParamdeep Bagga
Paramdeep Bagga
RSRitesh Kumar Srivastav
Ritesh Kumar Srivastav
Background: Sericin is a widely used protein in the pharmaceutical industry derived from the silkworm, Bombyx mori , and used for the treatment of various diseases and pathological conditions. It is the main ingredient of the Unani preparation khameera abresham. The study was conducted to evaluate the preclinical toxicity of the silk protein sericin in mice. Methods: In the acute toxicity study, sericin was administered once orally to different groups of animals at doses of 500, 1000, and 2000 mg/kg. Animals were observed for 14 days. In the sub-acute toxicity study, sericin was administered in mice for 4 weeks in the toxic group at doses of 500, 1000, and 2000 mg/kg, while in the recovery group it was administered for 4 weeks at doses of 500 and 2000 mg/kg followed by 2 weeks of distilled water administration. Results: In the acute toxicity study, the observed parameters showed no significant difference, and no mortality was reported. In the sub-acute toxicity study, there were no toxicological effects in any of the estimated parameters, while histopathological analysis showed inflammation in vital organs at the dose of 2000 mg/kg. Conclusions: Results of our acute toxicity study suggest that sericin is safe at all administered doses, while the sub-acute study suggests that the NOAEL (no-observed-adverse-effect level) of sericin is below 2000 mg/kg, at which it can be considered safe.

7 April 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
MSMohammad Shariq
Mohammad Shariq
TMTarique Mahmood
Tarique Mahmood
PKPoonam Kushwaha
Poonam Kushwaha
SPSaba Parveen
Saba Parveen
ASArshiya Shamim
Arshiya Shamim
MWMuhammad Wahajuddin
Muhammad Wahajuddin
Nanotechnology has emerged as an inspiring tool for the effective delivery of drugs to help treat Coronary heart disease (CHD) which represents the most prevalent reason for mortality and morbidity globally. The current study focuses on the assessment of the cardioprotective prospective ofanovel combination nanoformulation of sericin and carvedilol. Sericin is a silk protein obtained from Bombyx mori cocoon and carvedilol is a synthetic nonselective β-blocker. In this present study, preparation of chitosan nanoparticles was performed via ionic gelation method and were evaluated for cardioprotective activity in doxorubicin (Dox)-induced cardiotoxicity. Serum biochemical markers of myocardial damage play a substantial role in the analysis of cardiovascular ailments and their increased levels have been observed to be significantly decreased in treatment groups. Treatment groups showed a decline in the positivity frequency of the Troponin T test as well. The NTG (Nanoparticle Treated Group), CSG (Carvedilol Standard Group), and SSG (Sericin Standard Group) were revealed to have reduced lipid peroxide levels (Plasma and heart tissue) highly significantly at a level of p < 0.01 in comparison with the TCG (Toxic Control Group). Levels of antioxidants in the plasma and the cardiac tissue were also established to be within range of the treated groups in comparison to TCG. Mitochondrial enzymes in cardiac tissue were found to be elevated in treated groups. Lysosomal hydrolases accomplish a significant role in counteracting the inflammatory pathogenesis followed by disease infliction, as perceived in the TCG group. These enzyme levels in the cardiac tissue were significantly improved after treatment with the nanoformulation. Total collagen content in the cardiac tissue of the NTG, SSG, and CSG groups was established to be highly statistically significant at p < 0.001 as well as statistically significant at p < 0.01, respectively. Hence, the outcomes of this study suggest that the developed nanoparticle formulation is effective against doxorubicin-induced cardiotoxicity.

15 October 2017 in Russian Journal of Plant Physiology
Verified
Journal Article
Closed access
PDF file
ASArshiya Shamim
Arshiya Shamim
AFA. Farooqui
A. Farooqui
MSM. H. Siddiqui
M. H. Siddiqui
SMS. Mahfooz
S. Mahfooz
JAJ. Arif
J. Arif
To study the biochemical adaptive responses of the blue green algae Nostoc muscorum to the salinity- induced stress they were exposed to various concentrations (5, 10, 15, 20 or 200 mM) of sodium chloride (NaCl). A dose-dependent inhibition of total protein content showed an adverse effect of NaCl on the growth of N. muscorum. Four-day treatment of NaCl (5–20 mM) progressively increased the content of the total peroxide with subsequent increase of the superoxide dismutase (SOD) activity, proline and total phenol content only up to 10 mM NaCl. Higher concentrations of NaCl caused significant decrease in both the enzymatic and non-enzymatic antioxidants. Induction of two polypeptides of ~29.10 and 40.15 kD as well as upregulation of many polypeptides as compared to control indicates the induction of SOD and dehydrin-like proteins, which supports the theory of adaptation against the salt stress. Furthermore, adaptation of N. muscorum to lower concentrations (5–20 mM) of NaCl was also confirmed by no fragmentation of DNA while DNA fragmentation indicating programmed cell death (PCD) could only be seen at 200 mM NaCl for 12 hours. We hypothesized that proline may confer a positive role to combat salinity stress and the same was confirmed by treatment of the test blue green algae with exogenous proline (1 and 10 μM). The results exhibited 16% reduction in the level of total peroxides, which is a well known oxidative stress marker in the 10 μM proline-treated NaCl group as compared to direct exposure to NaCl.

20 February 2025 in Health Care Science
Verified
Journal Article
Open access
ANAshmun Nisha
Ashmun Nisha
ASArshiya Shamim
Arshiya Shamim
ARAleza Rizvi
Aleza Rizvi
TMTarique Mahmood
Tarique Mahmood
BGBhagyashree Goswami
Bhagyashree Goswami
SPSaba Parveen
Saba Parveen
Psychoneuroimmunology is a scientific discipline exploring the interconnectedness of the nervous system, emotion state, and immune system. The current review examines the distinct mechanisms through which the mind and body interact when subjected to stress. Manifestations of psychoneuroimmunological stress encompass symptoms such as depression, aggression, fear, and social withdrawal, which can exert a profound impact on physiological well‐being. Some observations suggest that humans and nonhuman animals exhibit similar stress‐related symptoms, aiding in the identification of pharmacological pathways and potential clinical implications of therapeutic interventions. Animal stress models are predicated on varying approaches aimed at eliciting a motivational state to navigate and confront aversive circumstances. The current review describes the diverse stress induction models that have been investigated internationally, incorporating an ethological perspective that involves evaluating innate and unpunished behaviors through methodologies like the elevated plus maze, elevated zero maze, light‐dark box, and open field test. Additionally, conditioned operant conflict tests, such as the Vogel conflict test, fall under the purview of learning and punishment models. This category encompasses classic conditioning models like fear conditioning, psychosocial models such as social defeat, and physical and chronic unpredictable stress paradigms. In this review, we critically evaluate existing cognitive and behavioral frameworks underpinning the development and perpetuation of stress‐related disorders, while also elucidating the impact of immune system responses on the mental and physical health of animals. The primary objective of this review is to elucidate the array of animal models employed in previous research and the testing protocols used to assess animal performance in stress induction scenarios, with the ultimate aim of reducing mortality rates among research animals.

2 November 2022 in Diabetology
Verified
Journal Article
Open access
PDF file
ASArshiya Shamim
Arshiya Shamim
HSHefazat H. Siddiqui
Hefazat H. Siddiqui
TMTarique Mahmood
Tarique Mahmood
TWTanveer A. Wani
Tanveer A. Wani
SZSeema Zargar
Seema Zargar
AVAKASH VED
AKASH VED
Diabetes mellitus is a metabolic disorder that is prima facie a cause for numerous macro and micro vascular complications. A common macroscopic complication associated with diabetes is cardiomyopathy. Cardiomyopathy refers to diseases of the heart muscle, where the heart muscle becomes enlarged, thick, or rigid. As cardiomyopathy worsens, the heart becomes weaker and is unable to conduct the right amount of blood through the body and maintain a normal electrical rhythm. This can lead to heart failure or arrhythmias. Chronic diabetes is one of the instigating factors behind the etiology of this cardiac complication. Type-II diabetes is associated with impaired glucose metabolism that increases the dependence of a diabetic heart on fatty acid oxidation to meet its functional demands, resulting in mitochondrial uncoupling, glucotoxicity, lipotoxicity and initially subclinical cardiac dysfunction that finally gives way to heart failure. The increasing diabetic population with cardiac disorders and the ironically decreasing trend in newer medications to counter this complication leave us at a crossroads for pharmacological management of diabetic cardiomyopathy. Keeping this in view, the present study proclaims a newly developed polyherbal combination (PHC) with three herbs, namely Tinospora cordifolia, Withania somnifera and Boerhavia diffusa based in olive oil and administered in fixed dose (PHC-6 and PHC-10) to screen its cardioprotective potential against a well-established experimental model for diabetic cardiomyopathy. The three herbs mentioned have been known through the traditional literature for their antidiabetic and cardioprotective roles, hence they became the obvious choice. The study follows an experimental model proposed by Reed et al., where the capacity of the β-cell is unobtrusively impeded without totally compromising insulin release, bringing about a moderate disability in glucose resilience. Various sophisticated parameters, namely intraventricular septum thickness of hearts, Western blot of α/β- MHC monoclonal antibody (Ab), cardiac pyruvate dehydrogenase (PDH) activity, medium chain acyl coenzyme A dehydrogenase (MCAD) enzyme, etc. showed promising results where treatment with PHC (PHC-6 and PHC-10) significantly (*** p < 0.001 and **** p < 0.0001) prevented the symptoms of cardiomyopathy in subsequent groups when compared to disease control group.